142 related articles for article (PubMed ID: 9158509)
41. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder.
Mungan MU; Canda AE; Tuzel E; Yorukoglu K; Kirkali Z
Eur Urol; 2005 Nov; 48(5):760-3. PubMed ID: 16005563
[TBL] [Abstract][Full Text] [Related]
42. Transitional cell carcinomas of the urinary bladder. A histopathological study.
Ahmed Z; Muzaffer S; Khan M; Kayani N; Pervez S; Husseini AS; Hasan SH
J Pak Med Assoc; 2002 Sep; 52(9):396-8. PubMed ID: 12532572
[TBL] [Abstract][Full Text] [Related]
43. Coincident vesical transitional cell carcinoma and prostatic carcinoma. Clinical features and treatment.
Androulakakis PA; Schneider HM; Jacobi GH; Hohenfellner R
Br J Urol; 1986 Apr; 58(2):153-6. PubMed ID: 3697629
[TBL] [Abstract][Full Text] [Related]
44. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer.
Clark PE; Stein JP; Groshen SG; Miranda G; Cai J; Lieskovsky G; Skinner DG
J Urol; 2004 Oct; 172(4 Pt 1):1342-7. PubMed ID: 15371837
[TBL] [Abstract][Full Text] [Related]
45. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?
Bartlett JM; Watters AD; Ballantyne SA; Going JJ; Grigor KM; Cooke TG
Br J Cancer; 1998 Jun; 77(12):2193-8. PubMed ID: 9649132
[TBL] [Abstract][Full Text] [Related]
46. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
47. [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence].
Janane A; Hajji F; Ismail TO; Elondo JC; Ghadouane M; Ameur A; Abbar M; Bouzidi A
Actas Urol Esp; 2011 Apr; 35(4):189-94. PubMed ID: 21419519
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological features of recurrence after radical cystectomy for patients with transitional cell carcinoma of the bladder.
Harada K; Sakai I; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Eto H; Miyake H
Int Urol Nephrol; 2006; 38(1):49-55. PubMed ID: 16502052
[TBL] [Abstract][Full Text] [Related]
49. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
50. The relationship between mast cell density and tumour grade in transitional cell carcinoma of the bladder.
Kim JH; Kang YJ; Kim DS; Lee CH; Jeon YS; Lee NK; Oh MH
J Int Med Res; 2011; 39(5):1675-81. PubMed ID: 22117967
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
[TBL] [Abstract][Full Text] [Related]
52. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
53. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
54. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
55. Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression.
Smits G; Schaafsma E; Kiemeney L; Caris C; Debruyne F; Witjes JA
Urology; 1998 Dec; 52(6):1009-13; discussion 1013-4. PubMed ID: 9836546
[TBL] [Abstract][Full Text] [Related]
56. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
57. Microcystic transitional cell carcinoma: a rare tumor of the urinary bladder.
Triki M; Ayadi L; Kallel R; Charfi S; Saguem I; Mhiri N; Boudawara TS; Gouiaa N
Pathologica; 2017 Sep; 109(3):151-155. PubMed ID: 29154374
[TBL] [Abstract][Full Text] [Related]
58. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival.
Li G; Yu J; Song H; Zhu S; Sun L; Shang Z; Niu Y
BMC Cancer; 2017 Aug; 17(1):530. PubMed ID: 28789622
[TBL] [Abstract][Full Text] [Related]
59. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study.
Liedberg F; Hagberg O; Holmäng S; Hosseini Aliabad A; Jancke G; Ljungberg B; Malmström PU; Åberg H; Jahnson S
Scand J Urol; 2015; 49(4):290-5. PubMed ID: 25624049
[TBL] [Abstract][Full Text] [Related]
60. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
